Introduction
Alzheimer's disease (AD) is a long-term neurodegenerative disorder that ranks sixth in the leading cause of all deaths in the United States and features amyloid β protein (Aβ) deposition and neurofibrillary tangles composed of aggregated phosphorylated tau protein (p-tau). 1 To date, an estimated 6% of 65-year or older people in the world are suffering from AD, which approximately accounts for 95% of AD cases. Despite tremendous research efforts towards AD, the underlying cause of AD remains elusive, and no treatment has been disclosed to stop or reverse the AD progress.
Recent studies have demonstrated that abnormalities of cholesterol homeostasis in the brain are strongly associated with several neurodegenerative diseases, such as AD, Parkinson's disease (PD) and Huntington's disease (HD). [2] [3] [4] [5] [6] As an important structural component of myelin as well as membranes of neurons and glial cells, cholesterol plays a central role in the process of dendrite outgrowth and myelination, maintenance of stability of microtubules, and synaptogenesis. 7 In the brain, cholesterol is mainly metabolized into 24S-hydroxylcholesterol (24-HC) by cholesterol 24-hydroxylase (CH24H) for elimination. CH24H is a --- Corresponding author. e-mail: Liang.Steven@mgh.harvard.edu monooxygenase, which is encoded by cytochrome P450 enzyme CYP46A1. It was reported that CYP46A1 polymorphism in the brain, which is deeply linked with increased Aβ and p-tau expression, could be a risk factor in AD pathology. 8, 9, 10 In addition, 24-HC could lead to cell death and short-term memory impairment. [11] [12] [13] Therefore, modulation of CYP46A1 activity may suppress neuronal cell death, Aβ deposition and p-tau accumulation by decreasing 24-HC formation, which thereafter serves as potential therapeutic pathway for AD. Mast et al have demonstrated that a series of marketed drugs could be re-purposed as potent CYP46A1 modulators including tranylcypromine, thioperamide, voriconazole, clotrimazole, and fluvoxamine. [14] [15] [16] [17] Some of these compounds were co-crystallized with CYP46A1 to elucidate their molecular interactions.
Positron emission tomography (PET) is a sensitive, quantitative, and non-invasive nuclear imaging tool to provide diagnostic information about the biological processes under disease conditions. [18] [19] [20] PET studies of CYP46A1 would allow to better understand in vivo biochemistry and physiology of cholesterol homeostasis, help to accelerate the translation of CYP46A1 modulators in clinical trials, as well as offer an in-depth insight into AD. Recently, we developed a facile "in loop" [ 11 C]CO2
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Alzheimer's disease positron emission tomography [ 11 C]CO2 fixation fixation technology, which directly takes advantage of an automated apparatus to enable 11 C-carbonylation in high efficiency. [21] [22] [23] [24] With this technology, we and other groups have successfully synthesized a series of PET tracers, such as [ 11 C]SL25.1188, [ 11 C]JNJ1661010 and [ 11 C]MAGL-2-11. 23, [25] [26] [27] As our combined interest in the CYP46A1-targeted PET ligand development and application of 'in-loop' [ 11 C]CO2 fixation, we present herein the facile synthesis of 11 C-labeled compound 1, which was recently patented as a potent CYP46A1 inhibitor (Figure 1) . 28, 29 Pharmacological and physicochemical evaluation of compound 1, as well as pharmacokinetic profiling via in vivo PET imaging and whole-body biodistribution experiments of [ 11 C]1 are reported in this work. 
Result and discussion

Chemistry
The synthetic route of CYP46A1 inhibitor 1 is shown in Scheme 1. In brief, we used commercially available tert-butyl 4-(4-phenylpyrimidin-5-yl)piperazine-1-carboxylate 2 as the starting material. Trifluoroacetic acid (TFA)-promoted removal of the tert-butyloxycarbonyl (Boc) group proceeded smoothly to give free amine 3 in 99% yield, which also served as the labeling precursor for follow-up [ 11 C]CO2 fixation. Subsequent installation of benzylaminocarbonyl group into 3 was readily achieved with the combination of benzylamine, triphosgene and N,Ndiisopropylethylamine (DIPEA) in THF. In all, the desired CYP46A1 inhibitor 1 was synthesized in 52% yield. 
Pharmacology and physiochemical property
We select compound 1 from a patent literature describing therapeutic drug molecules towards CYP46A1 for the treatment of neurodegenerative diseases. 28, 29 The compound showed 95% inhibitory activity towards CYP46A1 at 1 µM concentration and possessed a carbamide (urea) moiety which is amenable for radiolabeling using our 'in-loop' [ 11 C]CO2 fixation. [21] [22] [23] [24] Subsequent in silico calculation also indicated a favorable value of 60.3 Å for topological polar surface area (tPSA). Multi-parameter optimization (MPO) has been widely utilized in the CNS drug discovery to evaluate brain permeability. 30 Our test compound 1 showed a MPO score of 4.9, which together with other prediction indicated that 1 may have high likelihood to penetrate the bloodbrain barrier. Experimentally, compound 1 was subjected to potency evaluation towards CYP46A1 in vitro with our previously developed method. 16, 31 Briefly, purified CYP46A1 (d(2-50)CYP46A1-4His) was reconstituted with varying concentrations of compound 1 , rat NADPH cytochrome P450 oxidoreductase and cholesterol. The hydroxylation reaction was started by nicotinamide adenine dinucleotide phosphate (NADPH) at 37 o C, and maintained at the same temperature for 30 minutes. Enzymatic reaction was terminated by addition of dichloromethane. The hydroxylation products extracted with dichloromethane were then subjected to GC-MS (gas chromatography-mass spectrometry) analysis with 24-OTMS d7cholesterol as internal standard. As depicted in Figure 2 , the Ki of compound 1 was determined to be 7.3 ± 0.1 µM. We postulated the discrepancy of binding affinity of compound 1 could be derived from different measurement methods. In all, although it is certain that a more potent compound is necessary to demonstrate high binding potential in PET study, a radiochemical application of our [ 11 C]CO2 fixation method based on compound [ 11 C]1 were carried out to provide preliminary pharmacokinetic profiling as an entry point for further design CYP46A1 ligands. 
Radiosynthesis and lipophilicity measurement
In virtue of the urea group, radiosynthesis of compound 1 could be directly carried out via our previously developed 'in-loop' [ 11 C]CO2 fixation strategy. 23, 24, 26 As shown in Figure 3 , [ 11 C]CO2 was first reacted with benzylamine to form a carbomate intermediate [ 11 C]5 with BEMP as the [ 11 C]CO2 trapping reagent. POCl3-mediated dehydration of [ 11 C]5 provided the isocyanide species [ 11 C]6, which, upon quenched with secondary amine 3, yielded the desired radioligand [ 11 C]1. It was found that the efficiency of this reaction is closely associated with the amount of benzylamine. Using 4.6 µmol of benzylamine, the desired product [ 11 C]1 was obtained in a poor radiochemical conversion (4% RCC), whereas the side symmetric product [ 11 C]7 was formed in 80% RCC (entry 1, Table 1 ). Decreasing the amount of benzylamine to 0.92 µmol successfully suppressed the formation of side product [ 11 C]7, and the RCC of [ 11 C]1 increased to 45% (entry 2). Further decrease of benzylamine loading by 50% led to an increased RCC to 61% (entry 3). For comparison, we also performed a vial-based [ 11 C]CO2 reaction for the radiosynthesis of [ 11 C]1. Unfortunately, merely trace product was obtained (entry 4), which further highlighted the advantage of our 'in-loop' [ 11 C]CO2 fixation method. Ultimately, [ 11 C]1 was isolated in 21% decaycorrected radiochemical yield (RCY) with excellent radiochemical purity (>99%) and high molar activity (>37 GBq/μmol). Excellent in vitro formulation stability was observed for [ 11 C]1, as evidenced by no radiolysis 90 min post formulation in saline containing 5% ethanol (Figure 4) . Lipophilicity of a specific drug is an important index to evaluate its permeability of the blood-brain barrier (BBB) with a favorable range from 1.0 to 3.5. [32] [33] [34] The lipophilicity of [ 11 C]1 (logD) was measured as 3.05 ± 0.02 via the 'shake flask' method, which is the liquid-liquid partition between phosphate buffered saline (PBS) and n-octanol. 35 
PET imaging studies in mice
With [ 11 C]1 in hand, we then performed dynamic PET acquisitions in CD-1 mice for 60 min. Representative PET images in the brain (0-60 min summed) and whole-body as well as timeactivity curves (TACs) are shown in Figure 5 and Figure S1 in the Supporting Information. [ 11 C]1 demonstrated limited brain uptake with a maximum standard uptake value (SUV) of 0.42 at 0.5 min, followed by a steady washout. Pretreatment of 2phenylcyclopropan-1-amine (3 mg/kg), a known CYP46A1 inhibitor, 14 reduced the uptake of [ 11 C]1 (~31% decrease of AUC, area under curve). These experiments indicated a marginal level of in vivo binding specificity for [ 11 C]1. 
Whole-body ex vivo biodistribution studies
To further probe the uptake, biodistribution and elimination of [ 11 C]1, whole-body ex vivo biodistribution was carried out in mice at four time points (5, 15, 30 and 60 min) post intravenous (IV) injection of the radioligand. As shown in Figure 5 and Table S1 in the Supporting Information, tracer [ 11 C]1 exhibited limited brain uptake, which is in line with the results from PET imaging studies. High radioactivity was accumulated in several organs including lungs, pancreas, small intestine, kidneys and liver (>10% ID/g, injected dose per gram of wet tissue), followed by fast washout. The radioactivity in small intestine reached a climax at 30 min followed by fast elimination, which together with high residue radioactivity in the small intestine and liver, suggested the urinary and hepatobiliary elimination pathway for [ 11 C]1. 
Conclusion
In this work, we have efficiently synthesized a novel CYP46A1 PET tracer [ 11 C]1 in high radiochemical yield (21%), excellent molar activity (>37 GBq/μmol) and radiochemical purity (> 99%) using 'in-loop' [ 11 C]CO2 fixation method. By PET imaging and ex vivo whole body distribution studies, we provided a pharmacokinetic profile (uptake, retention and clearance) of [ 11 C]1 in major organs, of which the brain exhibited low uptake (0.4 SUV) and marginal binding specificity in vivo. Further improvement of binding affinity and ADME properties are underway to develop new CYP46A1 ligands.
